Sphingosine as a New Antifungal Agent against Candida and Aspergillus spp.
Fahimeh Hashemi AraniStephanie KadowMelanie KramerSimone KeitschLisa KirchhoffFabian SchumacherBurkhard KleuserPeter-Michael RathErich GulbinsAlexander CarpinteiroPublished in: International journal of molecular sciences (2022)
This study investigated whether sphingosine is effective as prophylaxis against Aspergillus spp. and Candida spp. In vitro experiments showed that sphingosine is very efficacious against A. fumigatus and Nakeomyces glabrataa (formerly named C. glabrata ). A mouse model of invasive aspergillosis showed that sphingosine exerts a prophylactic effect and that sphingosine-treated animals exhibit a strong survival advantage after infection. Furthermore, mechanistic studies showed that treatment with sphingosine leads to the early depolarization of the mitochondrial membrane potential (Δψm) and the generation of mitochondrial reactive oxygen species and to a release of cytochrome C within minutes, thereby presumably initiating apoptosis. Because of its very good tolerability and ease of application, inhaled sphingosine should be further developed as a possible prophylactic agent against pulmonary aspergillosis among severely immunocompromised patients.
Keyphrases
- candida albicans
- oxidative stress
- mouse model
- reactive oxygen species
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- pulmonary hypertension
- biofilm formation
- clinical trial
- endoplasmic reticulum stress
- escherichia coli
- open label
- signaling pathway
- prognostic factors
- climate change
- mechanical ventilation